PharmaLundensis is a research company. Main focus is on the treatment of severe pulmonary diseases. The three diseases the company is specialised in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced lung failure. In addition, development is made on system that eliminates the release of pharmaceutical pollution. PharmaLundensis is based in Lund.

Quotes for PharmaLundensis AB

Right Now

+/-
0.024
%
3,82%
Latest
0.652
High
0.666
Low
0.63
Volume
9 253
Turnover (SEK)
6 049
Market Value (MSEK)
34,7
Time (Latest trade)
2025-04-10 13:09

Board

CEO

  • Staffan Skogvall

Chairperson of the Board

  • Björn Sivik (tf)

Board

  • Bo Wennergren
  • Björn Sivik
  • Staffan Skogvall
  • Stefan Ahlfors

Largest Owners

Name Capital % Votes % Date
Staffan Skogvall 51,56 51,56 2025-03-27
Vict Th Engwalls Stiftelse 2,61 2,61 2025-03-27
Arne Skogvall 2,09 2,09 2025-03-27
Arne Arvidsson 1,88 1,88 2025-03-27
Avanza Pension 1,14 1,14 2025-03-27
Nordnet Pensionsförsäkring 0,70 0,70 2025-03-27
Tommy Johansson 0,66 0,66 2025-03-27
Staffan Engelbert Bodén 0,57 0,57 2025-03-27
Merrick Lee Tabor 0,42 0,42 2025-03-27
Monica Billgert 0,42 0,42 2025-03-27
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

*Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

Key Numbers

*Compiled data from Millistream

Upcoming reports

  • 2025-05-01 Delårsrapport 2025-Q1

  • 2025-08-21 Delårsrapport 2025-Q2

  • 2025-11-20 Delårsrapport 2025-Q3

  • 2026-02-19 Bokslutskommuniké 2025